NEWS&VIEWS 23 VWR International Contribute to Haiti Recovery
As relief efforts continue following the catastrophic earthquake in Haiti, VWR International is to contribute essential first- aid and medical supplies to hospitals and clinics, including gloves, hand sanitisers and respirators valued at approximately $200,000. The recently-launched VWR Foundation will also make a financial contribution to Doctors Without Borders., in support of the volunteer doctors and nurses as they continue to provide urgent medical care to victims.
"The devastation of the recent earthquake has reminded all of us that we must band together to utilise our strengths in Haiti's time of weakness," said John M. Ballbach, Chairman, President and CEO of VWR and President of The VWR Foundation. "For the Company and now the Foundation, we will continue to support research, science education and health and well-being across the globe. We hope that our contributions to the volunteer doctors and nurses will provide them the relief they need to continue treating victims and saving lives."
TO FIND OUT MORE CIRCLE NO.
Strategies to Boost Life Science Business Growth
International Consultancy Group Bridge4Bio focused on assisting life sciences and biotechnology companies, is targeting four strategic areas to help both startups and established companies plan and grow their businesses globally. In terms of channel development the Group’s senior management team will helps clients find the appropriate distributor, or choose appropriate partners for OEM mergers or licensing deals to expand their business. Guidance with strategic marketing includes building and implementing a global business plan for developing new and existing product line channel strategies. Advice covers market promotions, communications and agreement negotiation, as well as IP protection for securing future opportunity. Assistance with global sourcing – for manufacturing, reduced costs, contract negotiation or investing in long-term global partnerships – as well as finding appropriate investors or partnership companies also come under the umbrella of services offered.
“Forming a partnership with Bridge4Bio allows life sciences and biotechnology companies, both large and small, to maximise their growth potential while working with tight budgets,” explained Hugh Douglas, Bridge4Bio’s President.
Douglas continued: “Bridge4Bio provides our clients the experience of a network of ten international life sciences and biotechnology consultants who have all experienced first- hand the start-up and growth challenges faced by life sciences and biotechnology businesses in global markets. We recognise that companies may not have the funds for high-priced consultants. The client pays us based on the success of the implementation which means that the up-front cost and risk is further reduced for our clients.”
80 NewsinBrief
Thermo Fisher Scientific, Inc reported that revenues increased 7% to a record $2.84 billion in the fourth quarter of 2009, compared with $2.65 billion in the 2008 quarter. The revenue growth reflects the impact of currency translation, which increased revenues by 3%, and the effect of acquisitions, which also increased revenues by 3%. Adjusted earnings per share (EPS) grew 5% to $0.91 in the fourth quarter of 2009, versus $0.87 in the 2008 quarter. Adjusted operating income for the 2009 quarter increased 4% versus 2008 results, and adjusted operating margin declined 60 basis points to 18.0%, compared with 18.6% in the 2008 period. GAAP diluted EPS was $0.65 in 2009, versus $0.67 in the year-ago period. GAAP operating income for the 2009 quarter was $324.3 million, compared with $322.5 million in 2008, and GAAP operating margin was 11.4%, compared with 12.2% a year ago. For the full year, revenues declined 4% to $10.11 billion in 2009, compared with 2008 revenues of $10.50 billion. The revenue decline reflects the impact of currency translation, which decreased revenues by 2%, and the effect of acquisitions, which increased revenues by 1%.
Waters Corporation (NYSE/WAT) reported fourth quarter 2009 sales of $429 million, an increase of 3% from sales of $418 million in the fourth quarter of 2008. In the quarter, foreign currency translation increased sales growth rate by 4% and on a currency neutral basis, sales decreased by 1% in comparison to the prior year's fourth quarter sales. On a GAAP basis, earnings per diluted share (E.P.S.) for the fourth quarter were $1.08, compared to $1.01 for the fourth quarter of 2008. On a non-GAAP basis, including the adjustments in the attached reconciliation, E.P.S. grew 5% to $1.12 from $1.07 in the fourth quarter of
2008.For the full year, sales for the Company were $1.50 billion, a decrease of 5% from sales of $1.58 billion in 2008. This decrease in sales includes the effects of foreign currency translation which reduced sales by 2%. E.P.S. for 2009 were $3.34 compared to $3.21 in 2008. On a non-GAAP basis, including adjustments in the attached reconciliation, E.P.S. grew 5% to $3.45 from $3.30 in 2008.
Corning Incorporated (Lowell, Mass., U.S) and Sartorius Stedim Biotech (Göttingen, Germany) are co-marketing and branding a full range of cell culture products through a combined product catalogue and are working together on numerous marketing and sales initiatives. The companies are also exploring best options and approaches for future research and development efforts and joint product development. “As competitive pressures in the cell culture industry continue to evolve and increase, it is critical that we are able to offer customers a full range of cell culture laboratory products spanning basic research to full scale production,” said Thomas Appelt, Vice President and General Manager, Corning Life Sciences. “Working together will enable us to provide customers with more options and increased access to innovative products and technologies, helping them further their research efforts and improve results,” added Reinhard Vogt, Executive Vice President and board member of Sartorius Stedim Biotech.
PerkinElmer, focused on the health and safety of people and the environment, announced that OneSource®
, a component of its Analytical Sciences and Laboratory
Services business, has entered into an agreement with global laboratory supply and distribution company VWR International to develop a joint service offering. This will provide maintenance and service support for laboratory equipment from pipettes and pH meters, serviced by VWR, to complex multi-component analytical instrumentation, such as Liquid Chromatography/tandem Mass Spectrometry (LC/MS/MS), serviced by OneSource.
Agilent and Varian have been granted conditional antitrust clearance from the European Commission for Agilent's proposed acquisition of Varian. As part of the European Commission's clearance decision, Agilent and Varian have committed to sell Varian's laboratory gas chromatography (GC) business; Varian's triple quadrupole gas chromatography-mass spectrometry (GC-MS triple quad) business; Varian's inductively coupled plasma-mass spectrometry (ICP-MS) business; and Agilent's micro gas chromatography (micro GC) business. The aggregate fiscal 2009 revenues of these four businesses were under US$100 million.
TO FIND OUT MORE CIRCLE NO. Hugh Douglas, Bridge4Bio’s President TO FIND OUT MORE CIRCLE NO.
Best Technical Service Support 2009 -Werke GmbH & Co KG based
The service provided by lab equipment manufacturer IKA®
in Staufen, Germany is regarded ‘excellent’ as determined by VWR International which awarded IKA®
the honour of ‘Best Technical Service Support 2009’ during its European Sales Conference.
The honour, based on meeting criteria such as fast and competent advice regarding applications or products and help with repairs or service appointment, clearly demonstrates VWR International’s recognition of the qualities and capabilities offered by the IKA service and sales teams, a spokesperson said.
TO FIND OUT MORE CIRCLE NO. 82 81 Schott to Build Packaging
Facility in Russia Schott Pharmaceutical Packaging will be opening a manufacturing facility for premium quality ampoules and vials in Russia. The new plant that is expected to go into operation at the end of 2010 will be located in Zavolzhe, near the Russian city of Nizhny Novgorod. “The new plant in Russia represents yet another important step in our global growth strategy in the area of pharmaceutical systems. This will allow us to further extend our leading position in the area of high- quality pharmaceutical packaging in Russia and we will be able to satisfy local demand even better in the future,” noted Professor Udo Ungeheuer, Chairman of the Board of Management of Schott AG.
The short project duration was made possible, among other things, by being able to make use of the administrative infrastructure of the existing Schott plant that manufactures flat glasses in Nizhny Novgorod. The company will employ around 60 employees in Russia initially. Plans call for this figure to increase to 200 by 2014. The company will then be able to produce several hundred million ampoules and glass vials made of Schott Fiolax®
glass tubing. The new,
modern plant will manufacture according to cGMP guidelines (‘Good Manufacturing Practices’) and the products will meet the high international standards for primary pharmaceutical packaging.
TO FIND OUT MORE CIRCLE NO. 84 83
READ ALL THE LATEST NEWS & VIEWS, ARTICLES AND NEW PRODUCT RELEASES ONLINE, VISIT:
WWW.LABMATE-ONLINE.COM
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92
